Pfizer Inc. (NYSE:PFE) Shares Bought by Jupiter Wealth Management LLC

Jupiter Wealth Management LLC grew its position in Pfizer Inc. (NYSE:PFE) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,750 shares of the biopharmaceutical company’s stock after purchasing an additional 4,000 shares during the period. Pfizer makes up approximately 1.0% of Jupiter Wealth Management LLC’s holdings, making the stock its 27th largest holding. Jupiter Wealth Management LLC’s holdings in Pfizer were worth $1,904,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of PFE. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter worth $2,328,986,000. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Starboard Value LP purchased a new stake in Pfizer during the 4th quarter worth $407,730,000. Raymond James Financial Inc. acquired a new stake in Pfizer in the 4th quarter valued at $274,694,000. Finally, Massachusetts Financial Services Co. MA raised its position in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $23.33 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $132.66 billion, a PE ratio of 16.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The business has a fifty day moving average of $23.38 and a 200-day moving average of $25.19.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the firm earned $0.82 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.37%. Pfizer’s dividend payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.